Welcome to our dedicated page for Generation Bio news (Ticker: GBIO), a resource for investors and traders seeking the latest updates and insights on Generation Bio stock.
Generation Bio Co. has reported biotechnology and corporate-status developments tied to its historical focus on genetic-medicine approaches for T cell-driven autoimmune diseases. Company updates have covered the ctLNP cell-targeted lipid nanoparticle delivery system, siRNA delivery to T cells, operating and financial results, stock and listing-related actions, equity awards, and leadership transitions.
Later public disclosures also place GBIO in a corporate transition context, with strategic-alternatives language followed by regulatory records addressing delisting and Exchange Act deregistration notices for its common stock.
Moderna and Generation Bio have formed a strategic collaboration to develop novel nucleic acid therapeutics. Moderna has secured an option to license Generation Bio's lipid nanoparticle technology for two immune cell and two liver programs, with the possibility of a third. As part of the deal, Generation Bio will receive a $40 million upfront cash payment, along with a $36 million equity investment from Moderna, which will also fund all research and development activities. The collaboration aims to enhance the delivery of genetic medicines, targeting both immune cells and liver tissues.
On March 21, 2023, Generation Bio (Nasdaq:GBIO) announced its participation in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines. The virtual event will occur on March 28 at 10:00 a.m. ET.
Generation Bio is focused on developing genetic medicines for rare and prevalent diseases. Their innovative platform features closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a proprietary cell-free rapid enzymatic synthesis (RES) process. This technology aims to provide durable, redosable treatments potentially capable of producing hundreds of millions of doses, thus broadening access to genetic therapies globally.
Generation Bio (Nasdaq:GBIO), a biotechnology firm focused on genetic medicines, announced that Geoff McDonough, M.D., the president and CEO, will speak at the Gene Therapy panel during the 43rd Annual Cowen Healthcare Conference. This event is scheduled for March 6th at 10:30 a.m. EST in Boston, MA. A live webcast will be accessible on the company's investor website, with a replay available for 30 days post-event.
Generation Bio aims to provide innovative treatments for rare and prevalent diseases using its proprietary non-viral genetic medicine platform. This includes closed-ended DNA (ceDNA) technology and cell-targeted lipid nanoparticle delivery systems.
Generation Bio Co. (Nasdaq: GBIO) announced strategic priorities for 2023 and reported its 2022 financial results. The company aims to lead in non-viral DNA therapeutics, focusing on optimized delivery systems to enhance drug efficacy. A strong cash balance of $279.1 million is expected to fund operations into 2025. For 2022, the company reported a net loss of $136.6 million or $2.35 per share, with R&D expenses of $96.7 million. Upcoming plans include demonstrating Factor VIII expression in non-human primates and developing novel lipid nanoparticle systems for targeted therapies.
Generation Bio (Nasdaq: GBIO) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference scheduled for January 10, 2023, at 4:30 p.m. PST in San Francisco, CA. The company focuses on innovative genetic medicines targeting rare and prevalent diseases. A live webcast of the presentation will be available on the investor section of their website. Generation Bio's platform features unique technologies designed to enable durable, redosable treatments with large genetic payloads for specific cell types.
Generation Bio Co. (Nasdaq: GBIO) reported a cash position of $301.2 million as of September 30, 2022, expected to fund operations into 2025. The company focuses on developing genetic medicines, particularly for hemophilia A, utilizing its proprietary delivery system. Third quarter R&D expenses totaled $21.2 million, down from $22.0 million the previous year, while G&A expenses rose to $11.5 million, up from $9.7 million. The net loss narrowed to $31.3 million or $0.53 per share, compared to $31.9 million or $0.56 per share a year ago.
Generation Bio Co. (Nasdaq: GBIO) will participate in a fireside chat at the 2022 Jefferies Cell & Genetic Medicine Summit on September 29th at 10:30 a.m. ET in New York. A live webcast will be available on the company's investor website, and a replay will be accessible for 30 days post-event.
Generation Bio focuses on developing genetic medicines for rare and prevalent diseases using its unique platform, which includes closed-ended DNA (ceDNA) technology and a scalable manufacturing process. The aim is to provide durable, redosable treatments for patients worldwide.
Generation Bio Co. (Nasdaq: GBIO) has promoted Phillip Samayoa, Ph.D., to chief strategy officer. Dr. Samayoa, who joined the company in 2017, will lead corporate strategy and business development. His previous experience includes co-founding Generation Bio and roles at Merck and Flagship Pioneering. The company is focused on innovating genetic medicines using non-viral DNA therapeutics and targeted lipid nanoparticle delivery. Generation Bio aims to increase the availability of genetic medicines through its scalable manufacturing processes and unique technology platform.
Generation Bio Co. (Nasdaq: GBIO) reported second quarter 2022 financial results, focusing on advancements in its genetic medicine platform. The company has a cash balance of $312.2 million, projected to fund operations into 2025. Key developments include a new modular manufacturing strategy for its closed-ended DNA (ceDNA) product, enhancing productivity and capital efficiency. The net loss for the quarter increased to $37.9 million, or $0.66 per share, compared to $30.8 million or $0.55 per share in the previous year.
Generation Bio Co. (Nasdaq: GBIO) announced its participation in the virtual 2022 Wedbush PacGrow Healthcare Conference scheduled for August 9th at 9:45 a.m. ET. The event will include a live webcast available on the company’s investor website, with a replay accessible for 30 days post-event. Generation Bio is focused on advancing genetic medicines using its unique non-viral platform, which aims to provide durable, redosable treatments for rare and prevalent diseases, utilizing innovative technologies like closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticles.